Form 4: Neuronetics CFO Awarded 170,212 Restricted Stock Units

Neuronetics, Inc.'s EVP, CFO, and Treasurer, Steven Pfanstiel, was granted 170,212 restricted stock units, increasing his beneficial ownership to 570,212 shares.

Summary

• Steven Pfanstiel, the Executive Vice President, Chief Financial Officer, and Treasurer of Neuronetics, Inc. (STIM), acquired 170,212 shares of Common Stock.
• This acquisition was in the form of a Restricted Stock Unit (RSU) award, with each RSU representing a contingent right to receive one share of the Issuer's common stock.
• The RSUs are scheduled to vest on the earlier of June 30, 2027, or the termination of Mr. Pfanstiel's employment from Neuronetics without cause.
• The transaction date for this award was December 30, 2025, with a reported acquisition price of $0 per RSU.
• Following this transaction, Mr. Pfanstiel's beneficial ownership of Neuronetics' common stock increased to 570,212 shares.

Sentiment

Score: 7

Explanation: The grant of a significant RSU award to a key executive (CFO) is generally positive as it aligns management's long-term interests with shareholders and incentivizes retention and performance. It's a standard compensation practice.

Positives

• The grant of 170,212 Restricted Stock Units (RSUs) to Steven Pfanstiel, a key executive, aligns his long-term financial interests with those of Neuronetics' shareholders.
• Increased beneficial ownership by the EVP, CFO, and Treasurer demonstrates continued commitment and confidence in the company's future prospects.

Risks

• The vesting of the Restricted Stock Units (RSUs) is contingent on continued employment until June 30, 2027, or termination without cause, meaning the shares are not immediately available to the executive.

Future Outlook

The RSU award, with its multi-year vesting schedule, indicates a long-term commitment from a key executive, suggesting stability in leadership and an incentive for sustained performance over the vesting period.

Industry Context

Executive equity awards, such as Restricted Stock Units, are a common and standard practice across the medical device and technology sectors. These awards are utilized to attract, retain, and incentivize key talent, ensuring their performance is aligned with the company's growth objectives and shareholder returns.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for executive compensation is a standard practice across the healthcare and technology industries, comparable to compensation structures at companies like Medtronic or Boston Scientific, which often use similar long-term incentive plans to retain key executives.
• The vesting schedule, tied to continued employment or termination without cause, is typical for such awards, ensuring executive commitment over a multi-year period, similar to plans observed at peer companies in the medical technology space.

Stakeholder Impact

• Shareholders: Potentially positive, as the RSU award aligns executive incentives with long-term company performance and shareholder value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term company strategy.

Next Steps

• The 170,212 Restricted Stock Units will vest on the earlier of June 30, 2027, or the termination of Mr. Pfanstiel's employment from Neuronetics without cause.

Key Dates

Recommendation

This filing reports a routine executive compensation event (RSU grant) which, while positive for aligning management incentives, does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It reinforces a 'hold' stance for investors awaiting more substantive updates.

Keywords

Neuronetics, STIM, Restricted Stock Units, RSU, Executive Compensation, Insider Ownership, CFO, Steven Pfanstiel, Equity Award